Patient persistence with first-line antiglaucomatous monotherapy by Arias, Alfonso et al.
© 2010 Arias et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology 2010:4 261–267
Clinical Ophthalmology
O R I G I N A L   R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
261
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Patient persistence with first-line 
antiglaucomatous monotherapy
Alfonso Arias1 
Konrad Schargel2 
Fernando Ussa3 
Maria I Canut4 
Amelia y Belén Robles4 
Belén Martí Sánchez5
1Ophthalmology Department, 
Fundación Hospital Alcorcón,  
Madrid; 2Ophthalmology Department, 
Hospital de Torrevieja, Alicante; 
3Instituto Universitario de 
Oftalmobiología Aplicada, Valladolid; 
4Centro de Oftalmología Barraquer, 
Barcelona; 5Autónoma University  
of Madrid, Madrid, Spain
Correspondence: Belén Martí Sánchez 
Ronda Caballero de la Mancha 125,  
28034 Madrid, Spain 
Tel +34 9149 09454 
Fax +34 9149 09705 
Email martibelen@hotmail.com
Purpose: To identify the extent of persistence (period of time of continuous therapy with the 
drug prescribed) of glaucoma patients treated with prostaglandins (latanoprost, bimatoprost, or 
travoprost), or β-blocker (timolol) monotherapy.
Methods: An observational retrospective study of a 24-month follow-up in 191 patients 
(from four centers) was done to identify the time elapsed until patients discontinued their 
  antiglaucomatous treatment. The relevant information was extracted from patients’ medical 
charts. A descriptive analysis, a Kaplan–Meier survival analysis, and a Cox regression model 
were used to determine which drug was associated with greater patient persistence and to detect 
variables significantly influencing persistence.
Results: Descriptive analysis and survival curves showed that after 24 months, latanoprost was 
associated with a higher persistence in glaucoma treatment than the alternative agents: 81.6% 
versus 22.9% for bimatoprost, 65.4% for travoprost, and 60.5% for timolol (P  0.0001). 
  Persistence was significantly influenced by the antiglaucoma agent used as monotherapy (with 
a six-fold higher risk of treatment discontinuation during the follow-up period due to receiving 
bimatoprost instead of latanoprost; P  0.0001) and patient age (P = 0.001). Even though 
comorbidities could not be directly related to persistence, their occurrence was related to 
patient age. The main reasons for treatment discontinuation were lack of efficacy, development 
of intolerance and/or adverse events, which were significant in the bimatoprost group, 28.6% 
(P  0.001) and 48.6% (P  0.001), respectively.
Conclusions: Latanoprost shows higher patient persistence compared with travoprost, 
  bimatoprost, and timolol in routine clinical practice, and could lead to better control of intraocular 
pressure and lower associated economic costs.
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Introduction
Glaucoma, a chronic optic neuropathy, is characterized by a progressive loss of the 
retinal nerve fiber layer and visual field defects, related or not related to an increase of 
intraocular pressure (IOP) and, at present, is the third cause of irreversible blindness 
worldwide, with cataracts being the major cause.1
In Spain, the prevalence of glaucoma in the population over 40 years is 1.5%, and 
increases in individuals over 60 years of age.2 Primary open angle glaucoma, known 
also as simple chronic glaucoma, is the most frequent type, accounting for up to 60% 
of glaucoma cases.
IOP, past family history, age, race, male gender, cup-disk ratio, a high standard 
deviation (SD) on Humphrey’s visual field pattern, cardiovascular disease, and a thin Clinical Ophthalmology 2010:4 262
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central cornea thickness are the primary risk factors for 
glaucoma (Ocular Hypertension Treatment Study). IOP is 
the only known risk factor which can be modified to halt 
disease progression, and all antiglaucomatous treatments 
are targeted to IOP.
In spite of the American Ophthalmology Academy 
  recommendation to start with medical therapy, laser 
  trabeculoplasty, or filtration surgery for glaucoma, most 
patients receive initial treatment with a topical hypotensive 
drug.3 If the prescribed hypotensive drug effectively reduces 
IOP, it might be assumed that the patient would indefinitely 
continue using this ocular hypotensive drug with the aim 
of obtaining clinical improvement.4 Various studies have 
demonstrated that reduced IOP decreases the risk of loss of 
visual field5 and slows the process of ocular hypertension 
(OHT) progression to glaucoma.6 Even so, many patients 
withdraw from topical hypotensive treatment of their own 
accord.7–14
Marketed topical prostaglandins, including latanoprost, 
approved by the European Medicines Agency (EMEA) in 
1997, and bimatoprost and travoprost, approved in 2002 and 
2001, respectively, effectively reduce IOP levels by increasing 
aqueous fluid drainage through the uveal-scleral route.
The last version of the European Ophthalmology Society 
guidelines, published in 2008, states that the objectives of 
glaucoma treatment are to assure effective IOP management 
from the outset to prevent development of glaucomatous 
damage and to concentrate on treatment efficacy, tolerability, 
and compliance. Collection of data on clinical effectiveness, 
reflecting the clinical results of drugs used common medical 
practice conditions, has become increasingly important.
One of the most important contributors to good results in 
clinical practice is the continuous taking of the prescribed drug 
by the patient for the time period considered necessary. Thus, 
it is important to identify the likely duration of persistence 
(period of time for which the patient takes the prescribed 
drug) with antiglaucomatous medication. If the period of 
time of continuous medication is short, the therapeutic benefit 
will be minor, and lower than the benefit that might have 
been achieved if the patient had taken the medication for a 
longer time. This will cause a need for a second-line therapy 
prescription, thus increasing consumption of potentially 
unnecessary health care resources.15
Even though a number of factors may affect patient 
  persistence with treatment, one of the most important ones is 
local tolerability. When tolerability is poor, patients are very 
likely to discontinue their medication or put pressure on the 
ophthalmologist to change their treatment. Another important 
issue is clinical effectiveness of therapy; if IOP levels 
  continue to be high, the ophthalmologist will either opt for 
a change in medication or will add a second drug to reduce 
IOP further.16
The objective of this study was to evaluate the extent 
of patient persistence with the drugs most commonly 
used as monotherapy for glaucoma in Spain (latanoprost, 
  bimatoprost, travoprost, and timolol).
Materials and methods
An observational, retrospective study of glaucomatous 
patients was conducted in the ophthalmology departments of 
the Hospital de Torrevieja (Alicante), Centro de Oftalmología 
Barraquer (Barcelona), Fundación Hospital Alcorcón 
(Madrid), and Instituto Universitario de Oftalmobiología 
Aplicada (Valladolid).
The Ethics Committee for Clinical Research from the 
Fundación Hospital Alcorcón, Madrid, approved the protocol 
in December 2006. Due to the observational and retrospective 
nature of the study, for which data were obtained from 
review of medical charts, with no intervention or deliberate 
  modification of biologic, physiologic, psychologic, or social 
variables, patient informed consent was not required.
Using the hospital databases, clinical charts for 
  glaucomatous patients treated with commonly used 
  monotherapy (timolol 0.5% twice daily, latanoprost 
0.005%, bimatoprost 0.03%, or travoprost 0.004% once 
daily in the evening) were reviewed.
Inclusion criteria for the study were age over 18 years of 
age, a diagnosis of glaucoma or OHT, monotherapy with any 
of the study drugs between July 2003 and June 2004, and 
sufficient information in medical charts to monitor follow-up 
for at least 24 months after initiation of monotherapy. Patients 
may or may not have received antiglaucomatous treatment 
before the date of study initiation. Patients who had received 
concomitant antiglaucomatous treatment during the study 
period or whose medical charts did not contain reliable data 
for at least 24 months after monotherapy initiation were 
excluded.
Details of age, gender, time from diagnosis of glaucoma, 
last recorded IOP, associated comorbidities, previous 
  glaucoma treatments, and antiglaucomatous monotherapy 
were collected from medical charts.
Every selected patient had been followed up at three, 
six, nine, 12, and 24 months, so we were able to identify 
dates and reasons for treatment discontinuation. Thus, any 
  treatment changes during the 24-month follow-up period 
were able to be collected.Clinical Ophthalmology 2010:4 263
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A persistent patient was defined as one who had taken 
the prescribed drug as monotherapy continuously during 
the 24-month study period. For patients who did not persist 
with antiglaucomatous treatment for 24 months, the days to 
treatment discontinuation or to a medication change/referral 
for surgery by the ophthalmologist was recorded. A medica-
tion change was defined as any change in monotherapeutic 
agent used or addition of another ocular hypotensive agent. 
For patients who discontinued treatment at any time during 
the study, reasons for discontinuation (intolerance, adverse 
effects, poor compliance, patient request, or lack of efficacy), 
as well as any changes in the therapeutic approach of the 
attending ophthalmologist (treatment change, addition of a 
new therapy, or referral for surgery) were recorded.
Ophthalmology medical charts from July 2003 to June 
2004 were reviewed over a period of six months (from 
March to September 2007). A descriptive analysis of patient 
  sociodemographic and clinical characteristics was conducted, 
which enabled a comparison of the extent of patient persistence 
and clinical variables between patients who initiated 
  monotherapy with a prostaglandin or with a topical β-blocker 
(timolol). The distribution of each variable was analyzed in 
order to define possible recoding for both categoric and continu-
ous variables. Variable recoding was based on three criteria, 
ie, to define clinically significant categories, to reduce as far as 
  possible the number of categories, and to obtain the maximum 
homogeneity in the number of cases in each category.
To assess patient persistence with the study drug, 
a Kaplan–Meier survival analysis was done to estimate the 
persistence curves for patients treated with the different 
study medications over 24 months. To identify the statistical 
  significance of patient persistence with the different study 
drugs, Log-Range, Tarone–Ware, and Breslow contrast 
tests were used. Finally, a Cox regression model was used 
to identify the predictive effect of variables on the degree of 
patient persistence, with time to discontinuation as a dependent 
variable, and age, gender, concomitant drugs, associated 
comorbidities, IOPs, time from diagnosis of glaucoma, 
previous glaucoma treatments, and antiglaucomatous 
monotherapy (latanoprost reference group) as independent 
variables. For the statistical analysis, the SPSS statistical 
program was used (version 14.0; SPSS Inc., Chicago, IL).
Results
Of 191 patients who fulfilled our inclusion criteria, 
87 had been initiated on treatment with latanoprost, 
35 with bimatoprost, 26 with travoprost, and 43 with timolol. 
Demographic and clinical characteristics of these patients are 
summarized on Table 1.
Approximately 60% of patients were female, and a 
  statistically significant difference in gender ratio was found 
among the different treatment groups (P = 0.002). Mean 
patient age was 66.4 years (SD 14.0); the bimatoprost group 
showed the highest mean age, but age differences between 
Table 1 Characteristics of study patients
Latanoprost  
(n = 87)
Bimatoprost  
(n = 35)
Travoprost  
(n = 26)
Timolol  
(n = 43)
P value
Age (years), mean ± SD 64.8 (12.8) 68.5 (14.05) 67.5 (16.8) 67.5 (14.4) NS
Gender, n (%) 0.002
  Males 30 (34.5) 24 (68.6) 7 (26.9) 21 (48.8)
  Females 57 (65.5) 11 (31.4) 19 (73.1) 22 (51.2)
Last IOP value (mmHg),  
mean ± SD
16.6 (2.7) 17.0 (2.9) 17 (2.5) 17.4 (3.4) NS
Glaucoma (years)*,  
median ± SD
2.5 (4.1) 2.8 (2.9) 1.6 (1.5) 1.4 (3.5) NS
Previous glaucoma treatment,  
n (%)
40 (46) 26 (74.3) 8 (30.8) 11 (25.6) 0.00011
Associated comorbidities, n (%) NS
  None 47 (54) 18 (51.4) 6 (23.1) 20 (46.5)
  Cardiovascular  
  (includes diabetes)
31 (35.6) 12 (34.3) 16 (61.5) 21 (48.8)
  Ophthalmologic 8 (9.2) 5 (14.3) 3 (11.5) 1 (2.3)
  Neurologic 1 (1.1) 0 (0) 1 (3.8) 1 (2.3)
Notes: *Time since glaucoma diagnosis (years). **Including diabetes mellitus.
Abbreviation: NS, not statistically significant.Clinical Ophthalmology 2010:4 264
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groups were not statistically significant. Overall mean IOP was 
16.9 mmHg (SD 2.9); no statistically significant differences 
by treatment were observed, although it should be noted that 
IOPs recorded in patients’ medical charts were not always 
recorded on a date close to the initiation of follow-up. The 
mean time elapsed from the date patients had become aware 
of the diagnosis of glaucoma was 3.7 years (SD 3.6).
Forty-four percent of patients had received previous 
  treatment for glaucoma. However, this percentage varied 
between treatments, the bimatoprost group having the 
  highest percentage (74.3%), followed by latanoprost (46%). 
Timolol was the drug most frequently prescribed as an initial 
  treatment after diagnosis, followed by brimonidine and 
carteolol. No significant differences were observed among 
treatment groups for comorbidities.
Numbers and rates of patient persistence throughout 
the study with the various prescribed drugs are shown in 
Table 2. Only 36.1% of patients discontinued their treatment. 
When comparing persistence with the different study drugs, 
six possible combinations were analyzed. Latanoprost 
was statistical significant versus bimatoprost and timolol 
(P = 0.0001 and P = 0.01, respectively); but did not achieve 
statistical significance versus travoprost (P = 0.058), with a 
difference in persistence of 16.2%. Bimatoprost was found 
to be inferior versus travoprost and timolol (P = 0.003 and 
P = 0.001, respectively); travoprost and timolol did not show 
statistical significant (P = 0.8). Percentages and statistical 
significance of the differences in persistence with the study 
drugs are shown on Table 3.
Figure 1 shows a Kaplan–Meier survival plot where 
patient persistence is assessed over the 24 months. Table 4 
shows percentages for treatment discontinuation. Differences 
were found between the four treatment groups for intolerance 
and/or adverse effects as well as for lack of efficacy variables 
(P  0.001). Fewer latanoprost-treated patients reported 
intolerance and/or adverse effects and fewer travoprost-
treated patients reported lack of efficacy. The bimatoprost 
group showed higher rates of lack of efficacy compared with 
latanoprost, travoprost, and timolol.
For all possible variables with a predictive and/or 
  modifying effect on patient persistence, only the choice of 
antiglaucomatous drug used in monotherapy and patient 
age were statistically significant. The risk of treatment 
  discontinuation during the follow-up period was six-fold with 
bimatoprost versus latanoprost (P  0.0001) and 2.4-fold 
for timolol versus latanoprost (P = 0.01). An increased risk 
of 3.2% per year was observed with patient age (P = 0.001). 
Other variables analyzed were not related to duration of 
persistence.
Discussion
This study indicated greater patient persistence with 
  latanoprost than with other prostaglandins or the β-blocker 
timolol in routine clinical practice.
This is the first research done in Spain on patient 
  persistence with antiglaucomatous treatment, and the obtained 
results are similar to those of studies conducted in other 
countries,12,17–20 indicating greater patient persistence with 
latanoprost as a topical hypotensive therapy for glaucoma, 
which might be due to three factors. First, latanoprost has 
been shown to be more effective in IOP reduction than other 
therapies;21–24 second, unlike timolol, latanoprost has a more 
convenient once-daily dosing schedule; and third, it has a 
lower rate of adverse effects, in particular for hyperemia, 
when compared with the other topical hypotensive drugs. 
Reported incidence rates for hyperemia in the clinical trials 
are 5%–10% for latanoprost,25 15%–45% for bimatoprost,26 
and 35%–50% for travoprost.21
In a study conducted by Tingey et al, age, life expectancy, 
associated comorbidities, and satisfaction with treatment 
were the factors found to influence persistence with 
  treatment and IOP control.18 The results of preliminary 
research have suggested that treatment with latanoprost is 
associated with greater persistence than with bimatoprost or 
travoprost,10,12,13,17,22–26 and this is possibly due to its better 
tolerability.10
In three independent, retrospective studies of US cohorts, 
each including over 1000 patients, and with follow-up 
periods between 18 and 30 months, patients who initially 
received latanoprost as a single agent continued treatment 
for significantly longer than patients treated with β-blockers, 
carbonic anhydrase inhibitors, or brimonidine.8–10
Table 2 Patient persistence with treatment
N (%) Latanoprost (n = 87) Bimatoprost (n = 35) Travoprost (n = 26) Timolol (n = 43) P
No treatment  
discontinuation
71 (81.6) 8 (22.9) 17 (65.4) 26 (60.5) P  0.0001
Treatment  
discontinuation
16 (18.4) 27 (77.1) 9 (34.6) 17 (39.5)Clinical Ophthalmology 2010:4 265
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Recent clinical trials have documented that a low 
IOP in glaucomatous patients contributes to visual field 
  preservation.5,27 Thus, low persistence with the ocular 
hypotensive drug will limit the clinician’s ability to prevent 
visual loss related to glaucoma. Use of prostaglandin 
  analogs, including latanoprost, bimatoprost, travoprost, and 
  unoprostone, is related to higher persistence compared with 
other marketed hypotensive agents.4,5
The concept of persistence with treatment allows better 
assessment of the effectiveness of a treatment, reflecting 
its use in daily practice and identifying any possible 
change (eg, treatment failure), regardless of the underlying 
cause.
The introduction of prostaglandins resulted in a simplified 
more convenient dosing schedule, enabling more effective 
IOP reduction. Furthermore, it resulted in surgery becoming 
a second-line treatment for glaucoma, to be used only when 
IOP levels cannot be controlled by these potent drugs.28 We 
now need to identify drugs for glaucoma with as few side 
effects as possible to ensure continuity of treatment.
In our study, 81.6% of latanoprost-treated patients had 
continued treatment at the end of the second year, while 
only 22.9% of bimatoprost-treated patients persisted. 
Patient persistence with travoprost and timolol was 
approximately 60%. These results are in agreement 
with those published by Diestelhorst et al14 who, in an 
  observational and retrospective review conducted in 
13 European centers, observed that patients who received 
initial treatment for primary open angle glaucoma or OHT 
with latanoprost as monotherapy continued taking their treat-
ment for a time period twice that of those patients who had 
received a β-blocker, underwent fewer changes of therapy, 
and achieved a greater mean IOP reduction. All these dif-
ferences were statistically significant (P  0.0001).
Discontinuation rates differed among the treatments. 
Fewer latanoprost-treated patients reported an ocular adverse 
event compared with those receiving bimatoprost, travoprost 
or timolol (P  0.001). These results are consistent with those 
published by Parrish et al where latanoprost also showed 
greater ocular tolerability.29 A possible factor influencing 
the poor efficacy of bimatoprost may be the patient having 
Table 3 Degree of patient persistence with the study drugs
n Persistence (%) Difference P value
Latanoprost 87 81.6 58.7 0.0001
Bimatoprost 35 22.9
Latanoprost 87 81.6 16.2 0.058
Travoprost 26 65.4
Latanoprost 87 81.6 21.1 0.01
Timolol 43 60.5
Bimatoprost 35 22.9 -42.5 0.003
Travoprost 26 65.4
Bimatoprost 35 22.9 -37.6 0.001
Timolol 43 60.5
Travoprost 26 65.4 4.9 0.8
Timolol 43 60.5
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received previous treatment, which might create a negative 
comparison for the patient.
The proportion of patients who had received previous 
treatment for glaucoma varied among the treatment groups, 
with the bimatoprost group having the highest percentage 
(74.3%), followed by latanoprost (46%). It would have been 
helpful to know why the bimatoprost group had the greatest 
proportion of previously treated patients but, unfortunately, 
the study did not gather this information.
One strength of this study was that it enabled patient 
  persistence with the study drugs to be quantified, an 
  important factor to bear in mind when deciding between 
pharmacologic options, which may result in improved disease 
  management.
Regarding variables related to persistence, it should be 
emphasized that, even though comorbidities did not appear 
to be directly related to persistence, patient age was found 
to be significantly related.
One of the study limitations is the absence of efficacy 
measurements (in terms of IOP reduction), in order to study 
whether this might be a factor influencing persistence. 
As previously mentioned, no reliable data on baseline IOP 
levels were available, from which effectiveness of the 
  treatments could have been calculated.
In conclusion, at present, multiple monotherapy and 
combination therapy options are available for glaucoma and 
OHT management. Thus, the strategy selected to maximize 
the clinical benefit while minimizing associated health 
expenses will be critical.
Latanoprost has shown greater patient persistence than 
travoprost, bimatoprost, and timolol in routine clinical 
practice, resulting in better control of IOP levels, and lower 
associated costs. This attributes should avoid the occurrence 
or progression of complications, improve quality of care for 
glaucomatous patients, and result in a considerable resource 
saving for the national health system.
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